5/9/2025

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell […]

Source: Yahoo

5/9/2025

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Source: Yahoo

5/9/2025

It's shaping up to be a tough period for Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ), which a week ago released...

Source: Yahoo

5/9/2025

The current volatile situation shouldn't preclude investors from buying stocks. Eli Lilly, Vertex, Meta Platforms, and Netflix all stand to enjoy solid growth. Market volatility and near-term uncertainty can be challenging to deal with these days -- or at any time.

Source: Yahoo

5/9/2025

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges. Learn why CRSP stock is a buy.

Source: SeekingAlpha

5/9/2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Vertex Pharmaceuticals (NASDAQ:VRTX).

Source: Yahoo

5/8/2025

Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day

Source: MarketWatch

5/8/2025

The Hartford Healthcare Fund (I Share) underperformed the S&P Composite 1500 Health Care Index during the quarter. Read more here.

Source: SeekingAlpha

5/8/2025

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more on why CRSP is a Sell.

Source: SeekingAlpha

5/7/2025

Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors

Source: MarketWatch

5/7/2025

Crispr Therapeutics AG shows promise with innovative gene therapies like CTX-310, strong cash reserves, and a bullish long-term outlook. Click for my CRSP update.

Source: SeekingAlpha

5/7/2025

Sales from VRTX's new drugs, Casgevy, Alyftrek and Journavx, in Q1 fell short of investor expectations.

Source: Yahoo

5/7/2025

Vertex missed Wall Street's Q1 estimates and announced a pause with an early-stage study of its mRNA cystic fibrosis drug. This biotech stock should still generate exceptional returns over the next few years. Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week.

Source: Yahoo

5/7/2025

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.

Source: Yahoo

5/6/2025

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX stock a Buy.

Source: SeekingAlpha

5/6/2025

? After-Market Activity: Super Micro Computer (SMCI) stock and Rivian Automotive (RIVN) shares fell after the companies released postmarket earnings, while Advanced Micro Devices (AMD) rose following its report.

Source: Yahoo

5/6/2025

The S&P 500 slipped 0.8% on Tuesday, May 6, 2025, falling for a second straight day as investors awaited news on U.S. tariff policies and prepared for tomorrow’s Federal Reserve announcement.

Source: Yahoo

5/6/2025

On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported lower-than-expected first-quarter 2025 earnings. Vertex reported first-quarter adjusted earnings per share of $4.06, down from $4.76 a year ago, missing the consensus of $4.32. The cystic fibrosis-focused company reported sales of $2.77 billion, missing the consensus of $2.85 billion. Total revenue increased by 3%, primarily driven by the continued performance of Trikafta/Kaftrio and an early contribution from the U.S. launch

Source: Yahoo

5/6/2025

Yahoo Finance host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute, including Uber's (UBER) partnership with Chinese robotaxi company Pony AI (PONY) in the Middle East, EVgo's (EVGO) stock boost from earnings, and Vertex Pharmaceuticals (VRTX) shares taking a hit after missing earnings estimates. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Source: Yahoo

5/6/2025

Vertex Pharmaceuticals (NasdaqGS:VRTX) recently reported a decline in net income and EPS for Q1 2025, despite a rise in revenue, which was accompanied by a large $379 million impairment charge related to its diabetes treatment program. Additionally, the company increased its full-year revenue guidance. Over the past month, Vertex's stock price moved up 5%, aligning it with broader market trends. The market's recovery, despite recent fluctuations and investors' awaiting clarity on tariffs and...

Source: Yahoo